How to Tackle Lupus Disease
Author: Davis Seme
As a result and consequently, this condition act against the bodies own tissues, causing inflammation. When these autoimmunes act against the own body tissues, they are so therefore referred to as autoantibodies.
The National Institute of health sciences put that Afro (black women) are more at risk of contracting the disease than their white counterparts. This notion comes from the recorded number of cases involving the blacks to be higher than that of whites. It also intimates that black women tend to develop the disease at a younger age. Complications that are more serious manifest are accorded statistically nine times more in women than in men.
One of its many forms is defined in X-linked form of the disease as a carrier type. Carrier types are those do not show outright disease symptoms but well patched in the human Body. In general, carrier mothers are healthy, only their progeny may have lupus. However, in some cases carriers may get recurrent mouth ulcers or even regular skin infections especially when exposed to the sun.
Some people find that they have problems with their hands in the cold with their skin becoming very white or blue colored.
Only occasionally, these mothers may have symptoms associated with lupus disease. In these carriers, lupus-like symptoms such as tiredness, skin rashes and joint pains can be diagnosed through blood test, although studies have shown either negative blood tests or only weakly positive blood tests.
There are two forms of the disease: discoid lupus erythematosus (or DLE) is largely confined to the skin. The second form of this condition, systemic lupus erythematosus (SLE) is more generalized. The systemic form of lupus can be a more unpredictable condition, which should be carefully monitored by a Rheumatologist (often in a special ‘lupus clinic’).
Manifestations and how to know if you have lupus
Blood tests are applied to verify into types of autoantibodies (anti nuclear antibodies (ANA), and antibodies to double stranded DNA (which makes up genes and chromosomes) which indicate the most vulnerable parts of the body.
Lupus attacks many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain molecular changes occur in the brains of people with lupus.
The antibodies that attack the DNA of people with lupus can also attack molecules that bind a particular neurotransmitter (glutamate) involved in nerve cell activity
While current lupus treatments work by suppressing the entire immune system, treatments such as rituximab selectively targets the subset of white blood cells, called B-lymphocytes that are at the root of the problem in lupus. People who have more serious complications associated with systemic lupus may be treated with steroid tablets or other drugs, which damp down the immune system (immunosuppressant medication). People on these medications need to be carefully monitored and have regular blood tests and consult their doctors.
Many people today can be diagnosed conclusively. There is hope for a significantly increased life span and improved quality of life. A number of genes associated with lupus risk and its severity have been discovered. Some of these are linked in patient populations at high risk of having lupus.
Basic study on animal models of lupus has documented the novel, targeted, and relatively less toxic therapy of utilizing short peptides (protein fragments) preceding the development of symptoms of lupus that has resulted in slowed onset of lupus kidney disease as well as prolonged survival and halting of the progression of kidney disease in those who already have lupus.
Most lupus related studies have proposed an array of steps that can be taken to deal with the disease.
In the future, identifying lupus patients at particular risk for severe disease before serious complications arise has implications for early diagnosis and treatment. Therefore, this calls for further research. Genetic studies that would allow the identification of those at risk for lupus so that interventions can be made earlier in the disease process will be very useful.
Today, the variations in disease, course and severity that are associated with women and people in minority populations can be eliminated if our understanding of health disparities is improved, and treatments can be targeted to all affected individuals in a personalized way. In addition, some people with lupus have kidney disease, while some have predominantly central nervous system disease. In the future, there will necessitate having therapies designed for specific problem of lupus patients.
Identification of lupus as well as chances limiting one’s susceptibility to the disease will allow preemptive strategies to be developed. Because antibodies in the blood precede diagnosis of lupus by many years, it will be important for instance if the ongoing prevention trial of lupus in children will become available. Equally therapies that preemptively shield the binding of antibodies to kidneys and brain thereby block the injury to organ targets that lupus causes